AbbVie May Not Get All of Allergan for Antitrust Reasons, Argus Analyst Toung Says

The transcript discusses a business deal involving Bristol Myers and Celgene, highlighting potential trust issues and market reactions. It explores the strategic decisions and challenges faced by Allegan, including clinical trial misfires and IP protection issues. The discussion also covers the future prospects of the deal, focusing on asset management and competition.

What challenges did Allegan face that led to the need for a solution?

In what ways might the assets of Allegan fit better with AbbVie?